Two matching body-filler spec sheets, one unresolved detail: Advance-H is 400 μm on the brand page but 450 μm on TradeKorea — and the CE claim and the manufacturer's identity remain unverified

Asked (summary):

Research the Remedium "Advanced S" and "Advanced H" products — what they are, how they differ, and what is known about their status and safety.

This report draws on 35 source-backed rows from 26 pages across 13 websites, gathered by web research on 2026-10-23. The products are most consistently styled ReMedium Advance-S (Soft) and Advance-H (Hard): South Korean cross-linked hyaluronic-acid body fillers, 10 mL single syringes at 20 mg/mL. Twenty-three rows carry commercial (brand or seller) claims; twelve carry regulator or peer-reviewed safety context.

All product specifications below are marketing claims from brand and seller pages, not clinical-trial findings. No product-specific peer-reviewed clinical study of Advance-S or Advance-H was identified in this search. This report is informational and not medical advice; administration should only be considered by appropriately licensed clinicians under applicable local rules.

Advance-S versus Advance-H, side by side

Circles are drawn to scale against claimed microbead particle size, in micrometres (μm). Hover any circle or spec row for its source.

Blue — Advance-S (Soft), marketed for breast/body contouring. Rust — Advance-H (Hard), marketed for buttock/hip volumizing. The dashed outline marks the conflicting 450 μm figure for Advance-H reported by TradeKorea against 400 μm on the ReMedium Korea brand page.

Particle-size discrepancy: ReMedium Korea lists Advance-H at 400 μm (remediumkorea.com), while the TradeKorea listing says 450 μm (tradekorea.com) — a 12.5% gap no page explains.

Manufacturer discrepancy: Forever18 presents the line as its own product and says it launched the Soft/Hard variants (forever18international.com), while German seller Jolifill names BioPlus Co. Ltd. as manufacturer (jolifill.de). Supply-chain identity is an unresolved due-diligence item.

Unverified certification: ReMedium Korea claims CE marking (remediumkorea.com), but none of the reviewed pages supplies a certificate number, notified body, scope, expiry, or public registry record that would let the claim be independently verified.

U.S. category status: FDA states it has not cleared or approved any dermal filler for body contouring and warns against fillers for large-scale body enhancement — a category/use position, not product-specific enforcement against ReMedium (fda.gov).

Safety context for off-face fillers: regulator and peer-reviewed sources report infection and abscess, migration, nodules and granulomas, interference with breast imaging, and vascular/embolic injury up to death for body-filler use (pmc.ncbi.nlm.nih.gov, plasticsurgery.org); the UK plans to restrict non-facial fillers, including liquid BBLs, to doctors only (gov.uk).

All 35 evidence rows

Category separates commercial (brand/seller) claims from regulator or peer-reviewed context.

Product / subject	Category	Key detail	Source

Method: 35 source-backed rows gathered by web research on 2026-10-23 from 26 URLs across 13 hosts (no single URL supports more than 5.7% of rows), combining ReMedium Advance-S/H product-page specifications (marketing claims: composition, particle size, duration, packaging) with regulator and peer-reviewed safety context for off-face injectable fillers. Long free-text fields are truncated in the table for space; follow each source link for the full page. Informational only; not medical advice.

This report was generated automatically by Keenable SELECT at a user's request, from publicly available web sources linked herein. Keenable does not review, verify, or endorse its contents and makes no representation as to accuracy, completeness, or timeliness; AI-based extraction may contain errors. Nothing in this report is investment, legal, financial, or other professional advice. All trademarks and referenced content remain the property of their respective owners; no affiliation or endorsement is implied. To report an error, rights concern, or request removal: legal@keenable.ai.